ArticleGut2022
Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma.
Article in Gut, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05870696 (Evaluation of the Serum Metabolite Based PrecogColo Dx Test for Advanced Colorectal Neoplasia Screening), which is not on this map. Cited by 194 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Serum Metabolite Based PrecogColo Dx Test for Advanced Colorectal Neoplasia Screening
Who cites it
194 citing papers in PubMed, 2 syntheses or guidelines pooled it, 260 citations in OpenAlex.
- The gut microbiota-obesity axis in the pathogenesis and prognosis of breast cancer.Annals of medicine · 2026Pooled it
- Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies.Alimentary pharmacology & therapeutics · 2025Pooled it
- Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.Gut microbes · 2026Review
- A machine-learning informed circulating microbial DNA signature for early diagnosis of esophageal adenocarcinoma.Gut microbes · 2026Article
- Oral‑gut axis in systemic disease: A barrier‑metabolism‑immunity three‑dimensional regulatory model (Review).International journal of molecular medicine · 2026Review
- Detection of Pancreatic Cancer via Specific Metabolite Markers: A Metabolomics Approach.Health science reports · 2026Article
- Article
- Clinical potential of the gut microbiome in oncology: a scoping review of treatment response, toxicity and biomarker development.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Research advances in the role of circulating microorganisms in gastrointestinal tumors (Review).Molecular and clinical oncology · 2026Review
- Distinct Gut Microbiome and Metabolome Profiles Associate with Differential Responses to Immunotherapy in Colorectal Cancer.Polish journal of microbiology · 2026Article
- Decoding the gut microbiota metabolite-matrix metalloproteinase-3 axis in breast cancer: a multi-omics and network pharmacology study.Molecular diversity · 2026Article
- Inference of upstream-mutation and metabolomic-signature causality identifies prognostic biomarkers and therapeutic targets in pancreatic cancer.Nature communications · 2026Article
- Decoding the human gut bacterial plasmids in colorectal cancer.Communications biology · 2026Article
- Article
- Probiotics in colorectal cancer: mechanisms, biomarkers, and adjunct strategies.Cancer biology & medicine · 2026Review
- Multi Omics Integration in Colorectal Cancer: From Molecular Insights to Precision Oncology.Cancers · 2026Review
- Machine Learning-Assisted Plasma Metabolomics Identifies a Five-Metabolite Panel for Colorectal Cancer Detection.ACS omega · 2026Article
- Beyond Feature Selection: Interpretable Machine Learning for Mechanistic Insights in Metabolomics.Biology · 2026Review
- Circulating Microbial Metabolites Predict Tumor Relapse and Chemotherapy Efficacy in Nasopharyngeal Carcinoma.MedComm · 2026Article
- Review
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo profile gut microbiome-associated metabolites in serum and investigate whether these metabolites could distinguish individuals with colorectal cancer (CRC) or adenoma from normal healthy individuals.
designIntegrated analysis of untargeted serum metabolomics by liquid chromatography-mass spectrometry and metagenome sequencing of paired faecal samples was applied to identify gut microbiome-associated metabolites with significantly altered abundance in patients with CRC and adenoma. The ability of these metabolites to discriminate between CRC and colorectal adenoma was tested by targeted metabolomic analysis. A model based on gut microbiome-associated metabolites was established and evaluated in an independent validation cohort.
resultsIn total, 885 serum metabolites were significantly altered in both CRC and adenoma, including eight gut microbiome-associated serum metabolites (GMSM panel) that were reproducibly detected by both targeted and untargeted metabolomics analysis and accurately discriminated CRC and adenoma from normal samples. A GMSM panel-based model to predict CRC and colorectal adenoma yielded an area under the curve (AUC) of 0.98 (95% CI 0.94 to 1.00) in the modelling cohort and an AUC of 0.92 (83.5% sensitivity, 84.9% specificity) in the validation cohort. The GMSM model was significantly superior to the clinical marker carcinoembryonic antigen among samples within the validation cohort (AUC 0.92 vs 0.72) and also showed promising diagnostic accuracy for adenomas (AUC=0.84) and early-stage CRC (AUC=0.93).
conclusionGut microbiome reprogramming in patients with CRC is associated with alterations of the serum metabolome, and GMSMs have potential applications for CRC and adenoma detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.